Diabetes treatment is constantly progressing, with new therapeutic options developing to improve patient outcomes. Recent research have focused on GLP-1 and GIP receptor agonists, a category of drugs that mimic the actions of naturally occurring hormones involved in bloodglucose regulation. These novel agents demonstrate significant potential in im

The burgeoning landscape of treatment for obesity and type 2 glucose intolerance is currently witnessing considerable attention surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant distinctions in their pharmacological profiles and clinical study results are emerging. Retatrutide,

Retaglutide and tirzepatide represent cutting-edge category of medications known as dual GLP-1 and GIP agonists. These agents regulate both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that play a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormone